| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
299,119 |
95,855 |
$11.48M |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
386,424 |
88,652 |
$5.12M |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
46,640 |
26,869 |
$1.34M |
| 99484 |
|
31,767 |
27,451 |
$763K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
6,725 |
5,244 |
$252K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
12,863 |
10,590 |
$244K |
| 90792 |
Psychiatric diagnostic evaluation with medical services |
3,314 |
2,797 |
$227K |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
2,921 |
2,062 |
$211K |
| 96156 |
|
3,849 |
3,557 |
$191K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
8,612 |
5,785 |
$190K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
3,882 |
2,553 |
$173K |
| 80305 |
|
13,427 |
10,492 |
$104K |
| 86580 |
|
14,094 |
12,062 |
$70K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
985 |
749 |
$62K |
| 81025 |
|
12,508 |
9,380 |
$58K |
| 98960 |
|
2,049 |
1,613 |
$20K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
1,372 |
992 |
$12K |
| G0472 |
Hepatitis c antibody screening, for individual at high risk and other covered indication(s) |
421 |
308 |
$12K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
558 |
454 |
$6K |
| 86703 |
|
455 |
334 |
$4K |
| 99072 |
|
12,654 |
3,251 |
$4K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
80 |
75 |
$3K |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
738 |
414 |
$3K |
| 90791 |
Psychiatric diagnostic evaluation |
28 |
28 |
$2K |
| 99202 |
Office or other outpatient visit for the evaluation and management of a new patient, straightforward |
81 |
72 |
$2K |
| 82075 |
|
47 |
43 |
$987.00 |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
76 |
71 |
$767.39 |
| 99215 |
Prolong outpt/office vis |
20 |
14 |
$752.08 |
| 888888 |
|
5,700 |
1,703 |
$0.00 |